Last reviewed · How we verify
Cohort 2: HL217 Ophathalmic Solution QID
Cohort 2: HL217 Ophathalmic Solution QID is a Small molecule drug developed by Hanlim Pharm. Co., Ltd.. It is currently in Phase 1 development. Also known as: 3mg/mL.
At a glance
| Generic name | Cohort 2: HL217 Ophathalmic Solution QID |
|---|---|
| Also known as | 3mg/mL |
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects (PHASE1)
- A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 2: HL217 Ophathalmic Solution QID CI brief — competitive landscape report
- Cohort 2: HL217 Ophathalmic Solution QID updates RSS · CI watch RSS
- Hanlim Pharm. Co., Ltd. portfolio CI
Frequently asked questions about Cohort 2: HL217 Ophathalmic Solution QID
What is Cohort 2: HL217 Ophathalmic Solution QID?
Cohort 2: HL217 Ophathalmic Solution QID is a Small molecule drug developed by Hanlim Pharm. Co., Ltd..
Who makes Cohort 2: HL217 Ophathalmic Solution QID?
Cohort 2: HL217 Ophathalmic Solution QID is developed by Hanlim Pharm. Co., Ltd. (see full Hanlim Pharm. Co., Ltd. pipeline at /company/hanlim-pharm-co-ltd).
Is Cohort 2: HL217 Ophathalmic Solution QID also known as anything else?
Cohort 2: HL217 Ophathalmic Solution QID is also known as 3mg/mL.
What development phase is Cohort 2: HL217 Ophathalmic Solution QID in?
Cohort 2: HL217 Ophathalmic Solution QID is in Phase 1.
Related
- Manufacturer: Hanlim Pharm. Co., Ltd. — full pipeline
- Also known as: 3mg/mL
- Compare: Cohort 2: HL217 Ophathalmic Solution QID vs similar drugs
- Pricing: Cohort 2: HL217 Ophathalmic Solution QID cost, discount & access